We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Dh Cyprotels Plc | LSE:0GCT | London | Ordinary Share | SE0007730650 | NUEVOLUTION ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.10 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
STOCKHOLM, May 22, 2019 /PRNewswire/ -- Nuevolution AB (publ) announces its report for the first quarter of 2019. The report is available on the company's home page (www.nuevolution.com). The following is taken from the quarterly report.
Financial summary
January - March | ||
SEK million |
2019 |
2018 |
Revenue from contracts with customers |
14.1 |
8.3 |
Total operating expenses |
-27.2 |
-31.3 |
Operating result |
-13.0 |
-22.8 |
Net result |
-12.0 |
-21.3 |
Basic and diluted earnings per share (SEK) |
-0.24 |
-0.50 |
Cash flow from operating activities |
-24.6 |
-25.6 |
Cash and cash equivalents |
86.2 |
90.8 |
Business and R&D summary
"During the quarter, our partnerships with Almirall have progressed very well leading to the achievement of a key milestone in the collaboration. In Q1/19, we also nominated the drug development candidate in the bromodomain BET BD1 selective inhibitor program (fibrosis, atopic dermatitis, possibly immunotherapy). With three programs at candidate stage and three well-functioning partnerships, I am also pleased to see the positive progress in our discussions for the next valuable partnership.", said Alex Haahr Gouliaev, CEO
Events occurred between 31 March and 22 May 2019
9 May 2019: Nuevolution's BET-BD1 selective inhibitor and candidate compound, NUE20798, shows positive effect on disease scoring and biomarker levels in an atopic dermatitis (eczema) mouse model
On Thursday, 23 May 2019 at 11:00 CET, the company's executive management will host a conference call and webcast discussion of the results and provide an update on the pipeline programs and partnering activities. Access to the event can be obtained as follows:
Please notice new time for conference call
LIVE access on Thursday 23 May at 11:00 CET
Telephone numbers:
SE: +46-85-05-58-352
DK: +45-7815-0108
UK: +44-33-3300-9030
US: +1-833-5268-380
Webcast will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com
REPLAY access
Webcast replay will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com
For more information, please contact:
Alex Haahr Gouliaev, CEO
Phone: +45 3913 0902
Email: ahg@nuevolution.com
Johnny Stilou, CFO
Phone: +45 8877 5973
Email: jost@nuevolution.com
Information about Nuevolution AB (publ)
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and develops its programs alone and in collaboration with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution's internal programs are focused on therapeutically important diseases targets within severe inflammatory diseases and cancer.
The information was sent for publication, through the agency of the contact persons set out above, on Wednesday 22 May 2019 at 07:00 CET.
Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com .
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/nuevolution/r/nuevolution-ab--publ--announces-its-results-for-the-first-quarter-of-2019,c2820192
The following files are available for download:
https://mb.cision.com/Main/13526/2820192/1048982.pdf |
View original content:http://www.prnewswire.com/news-releases/nuevolution-ab-publ-announces-its-results-for-the-first-quarter-of-2019-300854808.html
SOURCE Nuevolution
Copyright 2019 PR Newswire
1 Year Dh Cyprotels Chart |
1 Month Dh Cyprotels Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions